T1	Participants 68 101	patients with Parkinson's disease
T2	Participants 242 290	two groups of patients with Parkinson's disease.
T3	Participants 323 382	10 patients with a moderate motor impairment insufficiently
T4	Participants 462 518	eight patients with L-dopa-induced peak-dose dyskinesia.